Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

PARIS–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease … [Read more…]

Second Annual Pennsylvania Perinatal Quality Improvement Designation Awards Recognize 62 Hospitals

HARRISBURG, Pa.–(BUSINESS WIRE)–#maternalhealth–The Pennsylvania Perinatal Quality Collaborative (PA PQC) is pleased to announce the recipients of its second annual Perinatal Quality Improvement Designation Awards which were presented at its annual conference in Altoona on May 21, 2025. Designation awards and levels are based on meeting quality improvement milestone criteria over a 12-month period, starting from … [Read more…]

Wolters Kluwer introduces Ovid Guidelines AI, transforming clinical guideline development with agentic AI

Ovid Guidelines AI will accelerate ASCO guideline research workflow with GenAI WALTHAM, Mass.–(BUSINESS WIRE)–Turning evidence from prospective research into structured medical recommendations through comprehensive evidence synthesis can be daunting for healthcare organizations. With the introduction of Ovid Guidelines AI, Wolters Kluwer is developing an agentic Generative AI (GenAI) workflow solution to accelerate this process and … [Read more…]

MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery

ATLAS ™ Sternal Repair Matrix is intended for challenging sternal fusion cases and IKON ™ Allogenic Matrix assists with soft tissue repair in high-risk patients EDISON, N.J. & SALT LAKE CITY–(BUSINESS WIRE)–MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), … [Read more…]

AI in Ultrasound Imaging Market Research 2025-2035 Featuring GE, Siemens Healthineers, Fujifilm, Canon Medical, EchoNous, Samsung, Butterfly Network, NovaSignal, Esaote, Exo AI, and Clarius – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global AI in Ultrasound Imaging Market: Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. Ultrasound imaging is a medical diagnostic technique that uses high-frequency sound waves to produce real-time images of the inside of the body. It is widely used in medical fields to visualize tissues, organs, and developing foetuses, … [Read more…]

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bernstein 41st Annual Strategic Decisions Conference on Wednesday, May 28, 2025. The company will take part in a fireside chat beginning at 3:30 p.m. ET. Investors and the general public are invited to listen to the session by visiting … [Read more…]

MarinHealth Launches Comprehensive Cardiothoracic Surgery Program as Part of Its Heart and Vascular Institute

Bringing World-Class Expertise and Exceptional Outcomes to the North Bay and Beyond GREENBRAE, Calif.–(BUSINESS WIRE)–#Marin—MarinHealth is proud to announce the launch of its new Cardiothoracic Surgery Program, as part of the MarinHealth Heart and Vascular Institute, to provide advanced surgical care for complex heart and thoracic conditions. Based at MarinHealth Medical Center, this program brings … [Read more…]

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in … [Read more…]

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J.–(BUSINESS WIRE)–CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program … [Read more…]

City of Hope Urges Bold Action to Address Rise in Cancer Among Younger Women

With Cancer Rates in Women Under 50 now 82% Higher Than Men, Leading National Cancer Research and Treatment Organization Calls for Age-Specific Research, Expanded Risk Assessments, and Lifetime Survivorship Support LOS ANGELES–(BUSINESS WIRE)–City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical … [Read more…]